Table 3.

IRRs comparing fracture incidence rates during the early-treatment period (0–3 months) with the on-treatment periods (4–12, 13–24, 25–36 and 37–48 months) in patients receiving anti-resorptive therapy

Time (months)	Denosumab		Oral bisphosphonates		Intravenous ibandronate		Intravenous zoledronate
	N	IRR (95% CI)	N	IRR (95% CI)	N	IRR (95% CI)	N	IRR (95% CI)
All fractures
4–12	120	0.62 (0.47–0.83)	249	0.61 (0.51–0.73)	36	0.69 (0.41–1.15)	16	0.91 (0.36–2.33)
13–24	83	0.50 (0.36–0.68)	192	0.56 (0.46–0.68)	34	0.78 (0.46–1.30)	9	0.79 (0.28–2.21)
25–36	42	0.44 (0.30–0.65)	95	0.51 (0.40–0.64)	23	0.98 (0.56–1.73)	2	0.34 (0.07–1.67)
37–48	18	0.33 (0.19–0.56)	56	0.58 (0.44–0.78)	6	0.57 (0.23–1.39)	3	1.15 (0.29–4.62)
Clinical vertebral fractures
4–12	43	0.38 (0.25–0.59)	99	0.47 (0.36–0.62)	8	0.35 (0.14–0.87)	6	0.68 (0.17–2.73)
13–24	29	0.30 (0.19–0.48)	61	0.35 (0.26–0.48)	10	0.52 (0.22–1.22)	4	0.70 (0.16–3.12)
25–36	14	0.26 (0.14–0.47)	27	0.28 (0.19–0.43)	8	0.78 (0.31–1.93)	–	–
37–48	9	0.32 (0.15–0.65)	20	0.41 (0.25–0.66)	3	0.65 (0.18–2.33)	–	–
Hip fractures
4–12	19	0.83 (0.38–1.84)	44	0.63 (0.41–0.97)	8	0.96 (0.29–3.18)	1	0.34 (0.02–5.46)
13–24	15	0.76 (0.33–1.74)	41	0.70 (0.45–1.09)	7	1.00 (0.29–3.42)	3	1.57 (0.16–15.09)
25–36	5	0.45 (0.15–1.33)	21	0.66 (0.39–1.12)	2	0.53 (0.10–2.92)	–	–
37–48	1	0.17 (0.02–1.36)	7	0.43 (0.19–0.96)	–	–	1	2.31 (0.14–36.93)
Wrist/forearm fractures
4–12	26	1.02 (0.49–2.12)	39	0.75 (0.47–1.22)	11	0.75 (0.29–1.94)	6	2.05 (0.25–17.01)
13–24	20	0.91 (0.43–1.95)	40	0.92 (0.57–1.49)	7	0.57 (0.20–1.63)	–	–
25–36	12	0.96 (0.42–2.23)	22	0.93 (0.53–1.61)	6	0.92 (0.31–2.73)	1	1.01 (0.06–16.14)
37–48	3	0.46 (0.13–1.68)	16	1.32 (0.71–2.42)	1	0.34 (0.04–2.77)	–	–

CI, confidence interval; IRR, incidence rate ratio; N, number of fractures